Acute Myelogenous Leukemia (AML, or Acute Myeloid Leukemia) is a blood cancer that affects primarily older adults and is associated with significant mortality. Patients with other blood malignancies or pre-malignancies, such as Myelodysplastic Syndrome (MDS), or patients who previously received cytotoxic treatments, commonly develop secondary AML that responds poorly to currently available treatments. In this one-page infographic, we provide a general overview of the AML pipeline landscape.

To download the infographic, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.